EGFR and non-small cell lung carcinoma: METHODS: This study included 106 NSCLC patients with stage IIIb–IV disease from the CAPTRA-Lung database, confirmed to have EGFR 19del mutations through next-generation sequencing (NGS) and receiving first-line osimertinib.